• 1. An integrated microfluidic platform for sensitive and rapid detection of biological toxins?
  Robert J. Meagher,Anson V. Hatch,Ronald F. Renzi,Anup K. Singh Lab Chip, 2008,8, 2046-2053
• 2. An approach to biodegradable star polymeric architectures using disulfide coupling?
  Jingquan Liu,Huiyun Liu,Zhongfan Jia,Volga Bulmus,Thomas P. Davis Chem. Commun., 2008, 6582-6584
• 3. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 4. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 5. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480

Recent Advances in the Study of 1-(1-Methyl-1H-pyrazol-4-yl)propan-1-amine (CAS: 936940-61-3)

The compound 1-(1-Methyl-1H-pyrazol-4-yl)propan-1-amine (CAS: 936940-61-3) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its pyrazole moiety and amine functional group, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and potential as a building block for more complex bioactive molecules.

One of the key areas of interest is the role of 1-(1-Methyl-1H-pyrazol-4-yl)propan-1-amine in the development of novel kinase inhibitors. Kinases are critical targets in cancer therapy, and the structural features of this compound make it a valuable scaffold for designing selective inhibitors. Recent publications have highlighted its utility in modulating specific kinase pathways, with preliminary data suggesting efficacy in preclinical models of certain malignancies.

In addition to its applications in oncology, this compound has also been investigated for its potential in central nervous system (CNS) disorders. The amine group in its structure allows for interactions with neurotransmitter receptors, making it a candidate for the development of drugs targeting conditions such as depression and anxiety. Recent in vitro and in vivo studies have demonstrated its ability to cross the blood-brain barrier and exhibit modulatory effects on key neurotransmitter systems.

The synthesis of 1-(1-Methyl-1H-pyrazol-4-yl)propan-1-amine has also been a focus of recent research. Advances in catalytic methods have enabled more efficient and scalable production of this compound, which is crucial for its further development and commercialization. Researchers have reported improved yields and purity through the use of novel catalysts and optimized reaction conditions, as detailed in recent patent applications and peer-reviewed articles.

Furthermore, the safety and toxicological profile of this compound have been under scrutiny. Recent toxicokinetic studies have provided valuable insights into its metabolic pathways and potential side effects, which are essential for its progression into clinical trials. These studies have identified key metabolites and have begun to elucidate the mechanisms underlying its pharmacokinetic behavior.

In summary, 1-(1-Methyl-1H-pyrazol-4-yl)propan-1-amine (CAS: 936940-61-3) represents a versatile and promising molecule in the realm of chemical biology and drug discovery. Its applications span from oncology to CNS disorders, and ongoing research continues to uncover new therapeutic potentials. With advancements in synthesis and a growing understanding of its pharmacological properties, this compound is poised to play a significant role in the development of next-generation therapeutics.

• 1007501-72-5(1-(1-ethyl-1H-pyrazol-4-yl)propan-1-amine)
• 1152548-59-8(2-methyl-1-(1-methylpyrazol-4-yl)propan-1-amine)
• 1216188-02-1(1-(1-methyl-1H-pyrazol-4-yl)cyclopentan-1-amine)
• 1017783-02-6(1-(1-methyl-1H-pyrazol-4-yl)propan-2-amine)
• 1396762-20-1(1-(1-Methyl-1H-pyrazol-4-yl)ethanamine hydrochloride)
• 1401426-05-8(1-(1-methyl-1H-pyrazol-4-yl)cyclopropan-1-amine dihydrochloride)
• 1338494-61-3(1-(1-methyl-1H-pyrazol-4-yl)cyclopropan-1-amine)
• 1154875-76-9(1-(1-methyl-1H-pyrazol-4-yl)ethane-1,2-diamine)
• 1500423-55-1(1-(1-methyl-1H-pyrazol-4-yl)cyclobutan-1-amine)
• 911788-33-5(1-(1-methyl-1H-pyrazol-4-yl)ethan-1-amine)